Cargando…

Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis

OBJECTIVE: Peripheral ulcerative keratitis (PUK) is a rare but severe ocular complication of rheumatoid arthritis (RA). It can be considered as an ocular manifestation of rheumatoid vasculitis (RV). Our case series aimed to evaluate the efficacy of rituximab (RTX) for PUK occurring in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonnet, Isabelle, Rousseau, Antoine, Duraffour, Pierre, Pouchot, Jacques, Nguyen, Chi Duc, Gabison, Eric, Seror, Raphaele, Marotte, Hubert, Mariette, Xavier, Nocturne, Gaetane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845725/ https://www.ncbi.nlm.nih.gov/pubmed/33510042 http://dx.doi.org/10.1136/rmdopen-2020-001472

Ejemplares similares

Lymphoma complicating rheumatoid arthritis: results from a French case–control study
por: Kedra, Joanna, et al.
Publicado: (2021)

Passive smoking in childhood and adulthood and risk of rheumatoid arthritis in women: results from the French E3N cohort study
por: Nguyen, Yann, et al.
Publicado: (2022)

Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database
por: Seror, Raphaele, et al.
Publicado: (2022)

Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis
por: Juge, Pierre-Antoine, et al.
Publicado: (2017)

Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry
por: Salmon, J H, et al.
Publicado: (2015)

Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis
por: Cohen, Stanley B., et al.
Publicado: (2018)

Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis
por: Sweeney, Shannon R, et al.
Publicado: (2016)

Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire
por: Pollastro, Sabrina, et al.
Publicado: (2019)

Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus
por: Reddy, Venkat, et al.
Publicado: (2015)

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
por: Winthrop, Kevin L., et al.
Publicado: (2019)

Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial
por: Sigaux, Johanna, et al.
Publicado: (2017)

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program
por: Mariette, Xavier, et al.
Publicado: (2018)

Effect of Fcγ-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis
por: Pál, Ildikó, et al.
Publicado: (2017)

Characteristics of Sjögren’s syndrome associated with rheumatoid arthritis
por: Hassold, Nolan, et al.
Publicado: (2022)

Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study
por: Alten, Rieke, et al.
Publicado: (2017)

Safety and Efficacy of Atacicept in Combination With Rituximab for Reducing the Signs and Symptoms of Rheumatoid Arthritis: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Pilot Trial
por: van Vollenhoven, R. F., et al.
Publicado: (2015)

Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study
por: Alten, Rieke, et al.
Publicado: (2017)

Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the ‘ORA’ registry
por: Nourisson, Cynthia, et al.
Publicado: (2017)

Predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis
por: Cheung, Peter P, et al.
Publicado: (2016)

Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts
por: Bouget, Vincent, et al.
Publicado: (2022)

A Risk Score to Detect Subclinical Rheumatoid Arthritis–Associated Interstitial Lung Disease
por: Juge, Pierre‐Antoine, et al.
Publicado: (2022)

Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register
por: Soliman, Moetaza M, et al.
Publicado: (2012)

The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries
por: Finckh, A, et al.
Publicado: (2015)

Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic
por: Druce, Katie L, et al.
Publicado: (2017)

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
por: Cohen, Stanley B, et al.
Publicado: (2020)

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Glucocorticoids and chronotherapy in rheumatoid arthritis
por: Cutolo, Maurizio
Publicado: (2016)

Management of Fatigue in Rheumatoid Arthritis
por: Pope, Janet E
Publicado: (2020)

Features of the Synovium of Individuals at Risk of Developing Rheumatoid Arthritis: Implications for Understanding Preclinical Rheumatoid Arthritis
por: de Hair, MJH, et al.
Publicado: (2014)

Rheumatoid factor isotypes in rheumatoid arthritis diagnosis and prognosis: a systematic review and meta-analysis
por: Motta, Francesca, et al.
Publicado: (2023)

Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials
por: Law-Wan, Johan, et al.
Publicado: (2021)

Biologicals in rheumatoid arthritis: current and future
por: Avci, Ali Berkant, et al.
Publicado: (2015)

Don’t neglect nutrition in rheumatoid arthritis!
por: Cutolo, Maurizio, et al.
Publicado: (2018)

Rheumatoid arthritis prevention: any takers?
por: Falahee, Marie, et al.
Publicado: (2021)

Overtreatment in rheumatoid arthritis: are there reasons for concern?
por: Ferreira, Ricardo J O, et al.
Publicado: (2022)

Intermetatarsal bursitis is frequent in patients with established rheumatoid arthritis and is associated with anti-cyclic citrullinated peptide and rheumatoid factor
por: Hammer, Hilde Berner, et al.
Publicado: (2019)

Differences in the Oral Microbiome in Patients With Early Rheumatoid Arthritis and Individuals at Risk of Rheumatoid Arthritis Compared to Healthy Individuals
por: Kroese, Johanna M., et al.
Publicado: (2021)

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors
por: Strand, Vibeke, et al.
Publicado: (2017)

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39
por: Spiliopoulou, Athina, et al.
Publicado: (2019)

Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients
por: Gossec, Laure, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bavi43f10caare30k9dat03746